First‐line tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib target angiogenesis and tumor proliferation through vascular endothelial growth factor (VEGF)/FGF receptor inhibition, but clinical efficacy is hampered by suboptimal responses and acquired resistance.3, 4. The gene discussed is VEGFA; the disease is neoplasm.